Comparative Pharmacology
Head-to-head clinical analysis: ARAZLO versus HEMSOL HC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAZLO versus HEMSOL HC.
ARAZLO vs HEMSOL-HC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAZLO (tazarotene) is a retinoid prodrug that is converted to its active metabolite, tazarotenic acid, which binds to retinoic acid receptors (RARs), specifically RAR-β and RAR-γ, modulating gene expression to normalize epidermal differentiation, reduce keratinocyte proliferation, and decrease inflammation.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation and immune response.
Topical: Apply 0.045% gel once daily to affected areas of the face.
Intravenous: 100 mg hydralazine hydrochloride (equivalent to 80.5 mg hydralazine base) administered over 30 minutes, every 6 hours as needed, for a maximum of 48 hours. Oral: 10–50 mg every 6 hours, adjusted based on response.
None Documented
None Documented
Terminal half-life approximately 29 hours, supporting once-weekly topical application.
Terminal elimination half-life: 1.2-2.5 hours; clinically, dose adjustments needed in hepatic impairment due to prolonged clearance
Primarily fecal excretion of unchanged drug (≥90%) and biliary elimination; renal excretion accounts for <2%.
Renal: >90% as unconjugated and conjugated metabolites; biliary/fecal: <10%
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid